Results 51 to 60 of about 22,419 (100)

Long-Standing Untreated or Inadequately Treated Seropositive Rheumatoid Arthritis in the Golden Age of Disease-Modifying Antirheumatic Drugs. [PDF]

Cureus
Arcilla CK, Kaeley GS, Thway M.
europepmc   +1 more source

Correlation of Hematological Indices and Acute-Phase Reactants in Rheumatoid Arthritis Patients on Disease-Modifying Antirheumatic Drugs: A Retrospective Cohort Analysis. [PDF]

J Clin Med, 2023
Pan YJ, Su KY, Shen CL, Wu YF.
europepmc   +1 more source

Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs [PDF]

, 2014
Tsutomu Takeuchi, Tsukasa Matsubara, Yukitomo Urata, Eiichi Suematsu, Shuji Ohta, Shigeru Honjo, Tohru Abe, Ami Yamamoto, Nobuyuki Miyasaka   +8 more
openalex   +1 more source

Diverging effects of tumor necrosis factor inhibitors and conventional synthetic disease-modifying antirheumatic drugs on immunosenescence and inflammageing in rheumatoid arthritis: a cross-sectional analysis. [PDF]

Immun Ageing
Schwarz T, Almanzar G, Völkl S, Feuchtenberger M, Leierer J, Schmidt C, Deininger F, Tony HP, Schmalzing M, Prelog M.   +9 more
europepmc   +1 more source

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. [PDF]

Korean J Intern Med, 2023
Cho SK, Kim H, Song YJ, Kim HW, Nam E, Lee SS, Lee HS, Park SH, Lee YA, Park MC, Chang SH, Kim HA, Kwok SK, Kim HR, Kim HS, Yoon BY, Uhm WS, Kim YG, Kim JH, Lee J, Choi J, Sung YK.   +21 more
europepmc   +1 more source

Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis

, 2009
Rachel O’Mahony, Mark Richards, C. Deighton, D. G. I. Scott   +3 more
openalex   +1 more source

Lipid profiles in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs [PDF]

, 2014
Anna Filipowicz‐Sosnowska, Piotr Głuszko, Robert Rupiński   +2 more
openalex   +1 more source

Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network. [PDF]

Front Pharmacol
Vitale A, Leone F, Caggiano V, Hinojosa-Azaola A, Martín-Nares E, Guaracha-Basañez GA, Torres-Ruiz J, Ayumi Kawakami-Campos P, Hissaria P, Callisto A, Beecher M, Dagna L, Tomelleri A, Campochiaro C, Frassi M, Crisafulli F, Franceschini F, Hernández-Rodríguez J, Gómez-Caverzaschi V, Araújo O, Sfriso P, Bindoli S, Baggio C, Sbalchiero J, Sota J, Tufan A, Vasi I, Piga M, Cauli A, D'Agostino MA, De Paulis A, Mormile I, Mayrink Giardini HA, Cordeiro RA, Gavioli F, Lopalco G, Iannone F, Montecucco C, Monti S, Ruiz-Irastorza G, Soto-Peleteiro A, Triggianese P, Gurnari C, Viapiana O, Bixio R, Vitetta R, Conticini E, La Torre F, Ragab G, Batu ED, González-García A, Peña-Rodríguez M, Bocchia M, Wiesik-Szewczyk E, Jahnz-Rózyk K, de-la-Torre A, Balistreri A, Frediani B, Fabiani C, Cantarini L.   +59 more
europepmc   +1 more source

Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis [PDF]

, 2015
Shunsuke Mori
openalex   +1 more source

Preferences for Tapering Biologic Disease-Modifying Antirheumatic Drugs Among People With Rheumatoid Arthritis: A Discrete Choice Experiment. [PDF]

Arthritis Care Res (Hoboken)
Chan SJ, Stamp LK, Treharne GJ, Cheung JMY, Dalbeth N, Grainger R, Stebbings S, Marra CA.   +7 more
europepmc   +1 more source